17th December, 2020 - Glycostem Therapeutics and Ghent University (UGent) have signed a license agreement for an inn
Glycostem and Ghent University sign license agreement on NK cell therapy technology
Glycostem announces treatment of first patient in pivotal phase I/IIa trial
15th December, 2020 – Glycostem today announced that the first patient has been dosed in its pivotal phase I/IIa trial of oNKord® for th
Glycostem initiates phase I/IIa trial of oNKord® in patients with Acute Myeloid Leukemia
20th November 2020 – Glycostem today announced the
FDA grants Glycostem’s oNKord® Orphan Drug Designation for Multiple Myeloma
12th October 2020 - Glycostem announces it has received the FDA’s Orphan Drug Designation (ODD) for treatment of Multiple Myeloma (MM) patients with its investigational product oNKord®.
Glycostem collaborates with LUMICKS
30th July, 2020 - LUMICKS has entered into a collaboration with Glycostem Therapeutics, the Netherlands, to improve immunotherapeutic drug development.
Glycostem enters contract with Autolomous to digitise manufacturing process
3rd June, 2020 – Autolomous Ltd, a leading edge developer of innovative digital solutions for manufacture of advanced medicines, and Glycostem Therapeutics BV, a clinical stage and leading Natural Killer (NK) cell manufacturing company, today a
Glycostem partners with Zelluna Immunotherapy
19th November, 2019 - Zelluna Immunotherapy, a biopharma company developing T-cell receptor (TCR) guided adoptive cell therapy products for the treatment of multiple solid cancers, and Glycostem Therapeutics BV, a clinical stage and leading Natural Killer (NK) cell manufacturing company, today announce that they have entered into a de
Glycostem welcomes Dr Rizwan Romee as US based advisor
12th September 2019 - Glycostem Therapeutics BV, a clinical stage and leading NK cell company,today announced to have welcomed Rizwan
Glycostem signs first commercial agreement for oNKord® and new CAR-NK co-development agreement
11th September 2019 - Glycostem Therapeutics BV, a clinical stage and leading NK-cell company, today announced the signing of a two agreements wit